Clinical Trials Directory

Trials / Conditions / KRAS G12D

KRAS G12D

10 registered clinical trials studyying KRAS G12D — 6 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingTCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
NCT07342738
Sun Yat-sen UniversityEARLY_Phase 1
RecruitingBBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1
RecruitingA Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
NCT05983159
Murdoch Childrens Research InstitutePhase 2
RecruitingPhase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914
AstraZenecaPhase 1
RecruitingRE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors
NCT06546150
Henan Cancer HospitalPhase 1
RecruitingPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924
Institut de Recherches Internationales ServierPhase 1 / Phase 2
Active Not RecruitingA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT05726864
Elicio TherapeuticsPhase 1 / Phase 2
Active Not RecruitingCAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
NCT05631899
Chinese PLA General HospitalPhase 1
CompletedA Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor
NCT04853017
Elicio TherapeuticsPhase 1
AvailableExpanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
NCT07083479
Elicio Therapeutics—